Literature DB >> 3898951

Cryptococcosis in the acquired immunodeficiency syndrome.

J A Kovacs, A A Kovacs, M Polis, W C Wright, V J Gill, C U Tuazon, E P Gelmann, H C Lane, R Longfield, G Overturf.   

Abstract

The clinical course and response to therapy of 27 patients with cryptococcosis and the acquired immunodeficiency syndrome were reviewed. Cryptococcosis was the initial manifestation of the syndrome in 7 patients, and the initial opportunistic infection in an additional 7. Meningitis was the commonest clinical feature (18 patients). Blood cultures and serum cryptococcal antigen were frequently positive. In patients with meningitis, leukocyte count, protein level, and glucose level in cerebrospinal fluid were frequently normal; cerebrospinal fluid India ink test (82%), culture (100%), and cryptococcal antigen (100%) were usually positive. Only 10 of 24 patients had no evidence of clinical activity of cryptococcal infection after completion of therapy; 6 of these 10 had relapses shown by clinical findings or at autopsy. Standard courses of amphotericin B alone or combined with flucytosine were ineffective. Cryptococcosis in patients with the syndrome is a debilitating disease that does not respond to conventional therapy; earlier diagnosis or long-term suppressive therapy may improve the prognosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3898951     DOI: 10.7326/0003-4819-103-4-533

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  120 in total

1.  Efficacy of SCH39304 in murine cryptococcosis.

Authors:  B I Restrepo; J Ahrens; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

2.  Pulmonary cryptococcosis.

Authors:  G B Huffnagle; M F Lipscomb
Journal:  Am J Pathol       Date:  1992-12       Impact factor: 4.307

Review 3.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

4.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

5.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

6.  Anticryptococcal resistance in the mouse brain: beneficial effects of local administration of heat-inactivated yeast cells.

Authors:  E Blasi; R Mazzolla; R Barluzzi; P Mosci; F Bistoni
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; L A Klug; W S Baughman; D Rimland; E A Graviss; R J Hamill; C Thomas; P G Pappas; A L Reingold; R W Pinner
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

Review 8.  Neurologic and psychiatric manifestations of HIV disease.

Authors:  H Hollander
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

9.  Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole.

Authors:  R J Coker; D Bell; B S Peters; S M Murphy
Journal:  Genitourin Med       Date:  1992-02

10.  Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice.

Authors:  M F Lipscomb; T Alvarellos; G B Toews; R Tompkins; Z Evans; G Koo; V Kumar
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.